The animal drug compounding market is gaining importance as veterinarians increasingly require customized therapies for animals whose needs cannot be adequately addressed by standardized commercial medicines. Compounding allows formulations to be adjusted for dosage, strength, delivery method, flavor, and species-specific requirements. The market was valued at USD 1.7 billion in 2025 and is estimated to reach USD 1.8 billion in 2026. It is projected to reach USD 3.3 billion by 2033, expanding at a CAGR of 8.5% from 2026 to 2033. North America dominated the market with a 37.3% revenue share in 2025.

Download a free sample copy of the Animal Drug Compounding market report to understand detailed coverage and inclusions in the final report

Personalization Creates Stronger Demand for Compounded Medicines

The growing complexity of veterinary care is a major factor supporting market expansion. Standardized medicines may not always provide appropriate strengths, dosage forms, delivery routes, or palatability for individual animals. Compounding enables veterinarians to develop customized formulations that can better address species-specific requirements and individual treatment needs.

This flexibility is particularly valuable for small mammals, geriatric animals, and animals receiving long-term treatment. Flavored suspensions, micro-dosed capsules, and transdermal gels can make medication easier to administer while supporting treatment adherence. Rising pet ownership and increasing veterinary spending are further strengthening demand for personalized therapies.

Commercial Drug Shortages Open Additional Opportunities

Shortages and discontinuation of commercial veterinary medicines are another important market driver. Manufacturing challenges, limited demand, regulatory changes, and supply-chain disruptions can create gaps in the availability of specialized treatments. Compounding pharmacies can prepare therapeutic alternatives when suitable commercial products are unavailable.

This role is particularly relevant for chronic, geriatric, and specialty treatments with limited substitutes. Supply-chain volatility and raw material shortages can further increase reliance on customized formulations, especially among specialty clinics and veterinary practices that require continuity of care.

Oral Administration Maintains a Strong Market Position

By route of administration, the oral segment dominated the market with a 66.3% revenue share in 2025. Oral formulations are widely used because they are convenient, non-invasive, and relatively easy for pet owners to administer at home. Liquids, powders, pastes, suspensions, capsules, and flavored chewables can be customized according to animal requirements.

By animal type, companion animals held the largest share at 73.0% in 2025. Dogs, cats, and other companion animals are generating demand for customized medications because of increasing pet ownership, higher veterinary expenditure, chronic conditions, and the need for formulations that improve medication adherence.

CNS Agents and Suspensions Lead Key Product Categories

CNS agents accounted for the largest product share, representing 33.3% of revenue in 2025. Compounded CNS medications are used for conditions including seizures, anxiety, neuropathic pain, and behavioral disorders. Customized suspensions, capsules, and transdermal formulations can provide alternatives when commercial dosage forms are unsuitable.

By dosage form, suspensions dominated with a 39.3% revenue share in 2025. Their flexibility allows pharmacists to adjust concentration, excipients, viscosity, and flavor, making them useful for animals that struggle with tablets or capsules. The hormones and substitutes segment is expected to be the fastest-growing product segment as customized therapies address endocrine and reproductive disorders.

Regulatory Compliance Remains a Critical Consideration

Regulatory oversight continues to shape the competitive environment. In the U.S., FDA guidance, state pharmacy-board requirements, sterile preparation standards, documentation, and quality controls influence compounding practices. Compliance can increase operating costs while supporting safety and quality.

The emergence of 503B outsourcing facilities also reflects the broader development of specialized compounding infrastructure. As the market expands, providers must balance customization and availability with rigorous quality and compliance requirements.

North America Leads While Asia Pacific Shows Strong Potential

North America maintained its leadership with a 37.3% revenue share in 2025, supported by established compounding pharmacies, veterinary infrastructure, pet ownership, higher veterinary spending, and demand for customized treatments. The U.S. held the largest country-level market share in 2025.

Asia Pacific is expected to register the fastest CAGR during the forecast period. Increasing pet ownership, expanding livestock populations, urbanization, rising disposable incomes, and greater demand for personalized veterinary care are supporting regional opportunities. China held the largest revenue share within the region, while India is also experiencing notable growth as its pet-care sector expands.

FAQs

1.       What is driving animal drug compounding market growth?

Growth is being driven by demand for personalized veterinary therapies, shortages and discontinuation of commercial veterinary drugs, increasing pet ownership, rising veterinary spending, and the need for species-specific dosage forms and delivery methods.

2.       Which region dominates the animal drug compounding market?

North America dominates the market, accounting for a 37.3% revenue share in 2025. The U.S. held the largest country-level market share, while Asia Pacific is expected to record the fastest CAGR during the forecast period.

Key Animal Drug Compounding Companies:

·        WEDGEWOOD PHARMACY

·        Vimian

·        Pharmaca.

·        Akina Animal Health

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

·         Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.

·         Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.

·         Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.

·         Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics

·         Investment Insights – Make investment decisions with data driven insights, powered by domain and technology

·         Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.